-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Podcasts|April 18, 2019

Understanding the Impact of Inappropriate Opioid Prescribing Practices

Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic.

Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic. A study published in the April issue of The American Journal of Managed Care® took a look at these prescribing patterns in Georgia, focusing on the Medicaid population in the state.

During this podcast, we speak with Jayani Jayawardhana, PhD, an associate professor in the college of pharmacy at the University of Georgia and lead author of the study, about the study's findings, their implications, and potential strategies for mitigating inappropriate prescribing in the Medicaid population.

You may need to log in to the website to access this podcast.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

Deaths Among Opioid Users: Impact of Potential Inappropriate Prescribing Practices

Read the study:


Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.